<DOC>
	<DOCNO>NCT01434420</DOCNO>
	<brief_summary>Breast cancer triple negative ( TN ; 15 % case ) characterize high histoprognostic grade , strong proliferation , strong metastatic power , bad prognosis form breast cancer . It however heterogenous group histological molecular level , also evolution . Most TN part basal breast cancer subcategory . Until , medical treatment base chemotherapy . Breast cancer constitutional mutation BRCA1 / BRCA2 ( 5 % breast cancer ) mostly basal type prognostic seem well could expect high grade tumour without hormonal receptor . They would much frequent TN group . However , day , prospective study lead estimate incidence , study intervention gene predisposition , well analyse link phenotype consequence germinal somatic level , term associate molecular change prognosis . The purpose study , prospective study , lead join analysis germinal level , search mutation main gene breast cancer predisposition ( BRCA1/2 , PALB2 , PTEN , PALB2 ) , tumour level ( tissue micro-array transcriptome ) , correlate result main clinical parameter . The 5 year relapse-free survival also estimate .</brief_summary>
	<brief_title>Triple Negative Breast Cancer : Study Molecular Genetic Factors</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>woman &gt; 18 non metastatic breast cancer triple negative 5 year followup sign informed consent cancer ( except situ ) metastases diagnosis impossibility followup</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>triple negative breast cancer</keyword>
</DOC>